Trophoblast organoids — self-organizing three-dimensional structures derived from first-trimester trophoblast stem cells — have emerged as the most physiologically relevant in vitro model of the human placenta. These self-renewing cultures recapitulate villous architecture, cytotrophoblast (CTB) stemness, syncytiotrophoblast (STB) differentiation, extravillous trophoblast (EVT) invasion, and hormone secretion in a single expandable system, opening the door to mechanistic studies of implantation failure, preeclampsia, and intrauterine growth restriction that were previously out of reach.
Placental Biology: Trophoblast Cell Types and Their Functions
The human placenta constitutes a fetomaternal interface of approximately 11 m² surface area at term, mediating gas and nutrient exchange, hormonal signaling, and immune tolerance between mother and fetus. All functional cell types of the placenta derive from a single progenitor — the villous cytotrophoblast (vCTB) — which differentiates along two distinct lineages.
The syncytiotrophoblast (STB) is the multinucleated epithelium covering the villous surface, formed by fusion of vCTBs. It is the primary site of maternal–fetal exchange and is the major endocrine compartment of the placenta, secreting human chorionic gonadotropin (hCG, encoded by CGB), progesterone, estrogen, human placental lactogen (hPL), and placental growth factor (PlGF). Key STB markers include CGB (hCG β-subunit), SDC1 (CD138/Syndecan-1), and ERVW-1 (Syncytin-1), which mediates cell–cell fusion.
The extravillous trophoblast (EVT) is the invasive lineage. EVT cells migrate from anchoring villi into the maternal decidua and the walls of uterine spiral arteries, remodeling these vessels from narrow, high-resistance conduits into wide, low-resistance channels that maximally supply the intervillous space. This process — spiral artery remodeling — is defective in preeclampsia and fetal growth restriction. EVT identity is marked by HLA-G (the unique EVT MHC class I molecule), MMP2, and ITGA5.
A third population, the villous CTB (vCTB), serves as the proliferative progenitor layer situated between the STB and the villous stroma. vCTBs replenish the overlying syncytium by fusion and give rise to EVT progenitors at the tips of anchoring villi. The transcription factors GATA3, TP63, and TFAP2C are reliable pan-CTB markers in first-trimester human placenta; CDX2 is also expressed but is less specific in human tissue compared with mouse trophoblast, where it is a more definitive lineage marker.
Trophoblast lineage dynamics shift substantially across gestation. During the first trimester (weeks 5–12), CTB proliferation and villous morphogenesis predominate; EVT invasion and the initiation of spiral artery remodeling are also concentrated in this window. From the second trimester onward, syncytialization and hormone production are sustained at high levels, with nutrient exchange capacity peaking in the third trimester as STB surface area is maximized. This early window is consequently the most relevant for modeling placentation and its disorders — and it is precisely the tissue from which trophoblast organoids are derived.
Based on articles retrieved from PubMed, Knöfler and colleagues provide a comprehensive review of these lineages and their regulatory networks: Knöfler et al., Cell Mol Life Sci 2019.
Human Trophoblast Stem Cell Derivation and Maintenance
A prerequisite for trophoblast organoid culture is a self-renewing CTB progenitor. The landmark 2018 paper by Okae and colleagues at Tohoku University established the first human trophoblast stem cell (hTSC) lines from first-trimester villous CTBs and from human blastocysts, demonstrating that activation of Wnt and EGF signaling combined with inhibition of TGF-β, HDAC, and ROCK was sufficient for indefinite CTB self-renewal. According to PubMed, these conditions enabled derivation of cell lines that give rise to all three major trophoblast lineages with transcriptomes closely matching primary trophoblast: Okae et al., Cell Stem Cell 2018.
hTSC identity is defined by co-expression of the transcription factors GATA3, TP63, TFAP2C, and YAP1. CDX2 is present but, as noted above, has lower lineage specificity in human than in mouse TSCs. Culture is performed on fibronectin-coated surfaces in a defined medium combining a ROCK inhibitor (Y-27632 or Fasudil), a TGF-β inhibitor (A83-01), EGF, the Wnt agonist CHIR99021, valproic acid (VPA), and additional small molecules; the precise combination was first reported by Okae et al. 2018 and is now widely used with minor laboratory-specific modifications.
From the hTSC state, differentiation to STB is induced by BMP4, cAMP elevation, and culture in the absence of self-renewal factors, while differentiation to EVT progenitors and invasive EVT requires growth in Matrigel or BME supplemented with Neuregulin-1 (NRG1) and withdrawal of CHIR99021 and A83-01, with subsequent NOTCH1 and then HLA-G expression marking progression through the EVT lineage.
Trophoblast Organoid Generation and Architecture
Trophoblast organoids were pioneered simultaneously in 2018 by two independent groups. Haider and colleagues at the Medical University of Vienna established long-term, self-renewing CTB organoid cultures from purified first-trimester cytotrophoblasts and showed that these organoids express markers of trophoblast stemness and proliferation, closely resemble primary CTBs at the level of global gene expression, spontaneously generate STB, and — on withdrawal of self-renewal factors — generate EVT progenitors (NOTCH1+) and invasive HLA-G+ EVT. According to PubMed: Haider et al., Stem Cell Reports 2018. In parallel, Turco and colleagues at the University of Cambridge generated genetically stable trophoblast organoids that organize into villous-like structures, secrete placental hormones including hCG, GDF15, and pregnancy-specific glycoprotein (PSG) as detected by mass spectrometry, form HLA-G+ EVT that invade three-dimensional matrices, and closely resemble first-trimester placenta at the methylome level. According to PubMed: Turco et al., Nature 2018.
Protocol overview. First-trimester placental explants are enzymatically dissociated to release primary CTBs. Cells are embedded in Matrigel or BME (basement membrane extract) domes and cultured in a defined trophoblast organoid medium based on Wnt activators (WNT3A, RSPO3), EGF, Noggin (BMP inhibitor), and the ROCK inhibitor Y-27632, with TGF-β inhibition (A83-01). Many laboratories use L-WRN conditioned medium as a practical Wnt/R-spondin/Noggin source. Organoids self-assemble within days, forming hollow spheroids typically 100–500 µm in diameter after 7–14 days. For passage, organoids are fragmented mechanically and re-embedded 1:3 approximately every two weeks; they can be biobanked in standard cryoprotectant and re-expanded from frozen stocks, making them suitable for longitudinal studies and multi-donor biobanks.
Polarity note. A critical structural difference from the in vivo placenta must be acknowledged: in trophoblast organoids grown in BME, the STB faces inward (lining the central lumen), whereas in vivo the STB faces outward toward the maternal intervillous blood space. This inside-out polarity is an inherent feature of organoid self-organization and represents a meaningful experimental limitation that must be considered when interpreting hormone secretion data and infection/transport assays.
Established functional outputs include: quantifiable hCG secretion in conditioned medium (measured by ELISA); progesterone and hPL production; EVT invasion in 3D Matrigel or fibrin gel assays; and CRISPR-Cas9 gene editing to model specific genetic perturbations.
Key Assays and Markers for Trophoblast Organoid Characterization
Rigorous characterization of trophoblast organoids requires a combination of immunofluorescence (IF) marker panels, secreted hormone assays, and functional readouts. The following markers and assays represent the field standard:
Immunofluorescence / immunohistochemistry: KRT7 (cytokeratin 7) is a robust pan-trophoblast marker used to confirm trophoblastic identity of all cells in the organoid. GATA3, TP63, and TFAP2C mark the CTB layer; CDX2 can be used additionally but with the caveat noted above regarding human specificity. SDC1 (CD138) and CGB (hCG β-subunit) identify the STB; HLA-G identifies EVT. Ki-67 marks proliferating CTBs in the outer layer. E-cadherin (CDH1) and N-cadherin (CDH2) mark the epithelial-to-mesenchymal transition during EVT differentiation.
Secreted marker ELISA: hCG in conditioned medium is the most widely used functional readout of STB activity and organoid viability. Human hCG ELISA kits allow quantification from organoid supernatants without harvesting the structures. PlGF (placental growth factor, encoded by PGF) is a pro-angiogenic factor secreted by STB and a key biomarker for preeclampsia risk assessment; human PlGF ELISA kits are available at BioHippo. Progesterone and hPL can be measured by ELISA from conditioned medium to confirm endocrine competence.
Invasion assay: EVT outgrowth from organoid buds into 3D Matrigel or fibrin matrices is quantified by brightfield or fluorescence microscopy. The distance, cell number, and HLA-G positivity of the invasive front are standard metrics.
Transcriptomics: Single-cell or single-nucleus RNA-seq of organoid populations is increasingly used to verify CTB, STB, and EVT subtype ratios and to confirm that organoid cell states match primary first-trimester trophoblast transcriptomes rather than transformed cell line profiles.
Applications: Disease Modelling, Pathogen Tropism, and Drug Testing
Preeclampsia. The sFlt-1/PlGF ratio is a validated clinical biomarker of preeclampsia (PE) risk: soluble FLT1 (sFlt-1/sVEGFR-1), an anti-angiogenic decoy receptor shed by the placenta, is elevated in PE, while PlGF (pro-angiogenic) is reduced. Trophoblast organoids derived from PE placentas or exposed to hypoxia show reduced EVT invasion, impaired syncytialization, and altered secretion profiles that recapitulate the disease phenotype, providing a patient-specific model for dissecting PE pathogenesis and testing therapeutic interventions.
Intrauterine growth restriction (IUGR). Organoids from growth-restricted pregnancies exhibit defective CTB proliferation and EVT outgrowth, enabling mechanistic investigation of the placental contribution to IUGR.
Viral and parasitic tropism. Zika virus infects trophoblast organoids with differential tropism across CTB, STB, and EVT populations, providing a tractable model for studying how the placenta acts as a barrier — or fails to act as one — against congenital viral infections. SARS-CoV-2 tropism at the trophoblast interface has also been investigated using organoid systems. Listeria monocytogenes placental invasion has been modelled in organoid-decidual co-cultures.
Pharmacology and toxicology. Drug transport across the syncytial layer can be studied in trophoblast organoids (with the caveat of the inverted polarity discussed above). The model is also suited to first-trimester-safe drug identification and reproductive toxicology screening, where animal placental anatomy is too divergent from human to extrapolate reliably.
Gestational trophoblastic disease. Comparison of normal trophoblast organoids with choriocarcinoma lines such as BeWo and JEG-3 — available in the Trophoblast Cell Lines collection — allows definition of the molecular differences between normal and malignant trophoblast differentiation.
Reagents for Trophoblast Organoid Research
Setting up or scaling trophoblast organoid work requires three categories of reagents. For cell models, the classical trophoblast lines BeWo, JEG-3, JAR, and HTR-8/SVneo remain valuable for rapid mechanistic assays alongside primary first-trimester explants; all are available in the Trophoblast Cell Lines collection. The L-WRN cell line (used to generate conditioned medium containing WNT3A, RSPO3, and Noggin) is available in the Placental & Trophoblast Research collection alongside the other niche components. For functional readouts, validated ELISA kits covering hCG, PlGF, and progesterone are available at BioHippo. For custom projects or larger-scale cell sourcing, the BioHippo research services team can assist with setup.
Frequently Asked Questions
What is a trophoblast?
A trophoblast is the specialized epithelial cell that forms the placenta. Trophoblasts arise from the outer layer (trophectoderm) of the early blastocyst and give rise to every functional cell type of the placenta — syncytiotrophoblast, extravillous trophoblast, and villous cytotrophoblast — rather than to the fetus itself, which develops from the inner cell mass.
How are trophoblast organoids different from monolayer trophoblast cultures?
Monolayer trophoblast cultures — including widely used lines such as BeWo, JEG-3, and HTR-8/SVneo — are fast and convenient but are transformed 2D monolayers that do not reproduce the layered villous architecture of the placenta or the full differentiation program from CTB to STB and EVT. Trophoblast organoids are self-renewing 3D cultures derived from primary first-trimester CTBs that spontaneously form villous-like structures, maintain CTB stemness, generate syncytiotrophoblast and extravillous trophoblast, and closely match the gene expression profile of primary first-trimester placenta.
What markers identify syncytiotrophoblasts?
Syncytiotrophoblasts are identified by CGB (the β-subunit of hCG), SDC1 (CD138/Syndecan-1), and ERVW-1 (Syncytin-1) by immunofluorescence or immunohistochemistry. Functionally, STB activity is quantified by hCG secretion into conditioned medium using a sandwich ELISA kit. The pan-trophoblast marker KRT7 labels all trophoblast subtypes and is used to confirm trophoblastic identity across the organoid.
What can trophoblast organoids model that animal models cannot?
Human trophoblast organoids recapitulate human-specific aspects of placentation that are absent in mouse and rat models: HLA-G-mediated immune tolerance at the maternal–fetal interface, human-specific spiral artery remodeling by EVT, and the hormonal profile of human pregnancy (hCG, hPL). Rodent placentas also differ fundamentally in hemochorial depth and villous structure. Trophoblast organoids from individual donors additionally enable patient-specific modeling of conditions such as preeclampsia and recurrent miscarriage — something that is not possible in inbred animal models.
How do you measure trophoblast organoid function?
The primary functional readout is hCG secreted into conditioned medium, which is quantified by ELISA and provides a non-destructive measure of STB activity and organoid viability over time. PlGF ELISA measures pro-angiogenic output and is relevant to preeclampsia research. EVT invasion depth and cell number in 3D matrix assays provide a quantitative measure of the invasive lineage. Transcriptomic profiling by scRNA-seq of dissociated organoids provides population-level identity verification across the CTB, STB, and EVT compartments.
References. Citations retrieved from PubMed. Okae H, et al. Derivation of Human Trophoblast Stem Cells. Cell Stem Cell. 2018;22(1):50–63.e6. doi:10.1016/j.stem.2017.11.004. Haider S, et al. Self-Renewing Trophoblast Organoids Recapitulate the Developmental Program of the Early Human Placenta. Stem Cell Reports. 2018;11(2):537–551. doi:10.1016/j.stemcr.2018.07.004. Turco MY, et al. Trophoblast organoids as a model for maternal–fetal interactions during human placentation. Nature. 2018;564(7735):263–267. doi:10.1038/s41586-018-0753-3. Knöfler M, et al. Human placenta and trophoblast development: key molecular mechanisms and model systems. Cell Mol Life Sci. 2019;76(18):3479–3496. doi:10.1007/s00018-019-03104-6.
